PositiveSelect™

Positive Bioscience

Patient		Physician	
Name : xxxxxxxxxx		Name : xx xxxxxxxxx	
Gender : M	Date of Birth : DD/MM/YYYY	Institute : xxxxxxxxx	

Diagnosis : NSCLC

Sample Type : Plasma	Sample Collection Date : DD/MM/YYYY		Sample ID : PB_CG_SG_XXXX-XX_XX
Test : PositiveSelect Lung	Technology : Illumina NGS	Coverage : 1000x	Report Date : DD/MM/YYYY

Patient Tumor Type Specific Genes

Gene	Genetic Alteration	Result
ALK-EML4 Rearrangements	No alteration detected	Negative
BRAF Mutation [p.V600E]	No alteration detected	Negative
EGFR Mutation Exon 18, 19, 20, 21	No alteration detected	Negative
ERBB2 Mutation [HER2] [Exon 20 insertion]	No alteration detected	Negative
ERBB2 Amplification [HER2]	No alteration detected	Negative
KRAS Mutation [Codon 12]	No alteration detected	Negative
MET Amplification	No alteration detected	Negative
MET mutation [Exon 14 skipping]	No alteration detected	Negative
RET Rearrangements	No alteration detected	Negative
ROS1 Rearrangements	No alteration detected	Negative

Note: Genomic alterations in the 8 genes related to cancer type (Lung Cancer) as listed in NCCN guidelines are reported here.

Positive Biosciences Ltd.

Registered Office: 645, Anna Salai, Thousand Lights, Chennai - 600 006. Tel.: 044-28290187

Corporate Office: 1st Floor, Kohinoor City Mall, Gate No. 1, Opp. Don Bosco School, Premier Road, Kirol Road, Kurla (West), Mumbai - 400 070.

Toll Free: 1800 1235 835 Website: www.positivebioscience.com Email: info@positivebioscience.com CIN: U93000TN1995PLC030290

PositiveSelect™

Positive Bioscience

About PositiveSelect Lung

PositiveSelect Lung is a targeted-NGS based diagnostic test, which tests for all four categories of genomic alterations; single nucleotide variations,indels, copy number variations, structural variations, in the 8 genes as listed above. It adds the advantage of making available a comprehensive molecular testing solution as indicated in the guidelines with specificity and sensitivity higher than the conventional platforms.

The PositiveSelect Lung test, has been designed to work both on FFPE and liquid biopsy, thus ensuring the criteria for sample procurement and requirement is made convenient. The blood collection tube that comes with the test, ensures low risk of sample degradation and extraction of adequate ctDNA for the test. The custom-designed assay enriches all the 8 recommended gene targets from the cfDNA and further is sequenced in a depth of 1000X on the Next- Seq Illumina NGS platform. The end result involves massive parallel sequencing of all the enriched cancer-specific target regions along with flanking introns.

Analyzed by:

Scientific Officer

Verified by:

Sr. Scientific Officer

Positive Biosciences Ltd.

Registered Office: 645, Anna Salai, Thousand Lights, Chennai - 600 006. Tel.: 044-28290187

Corporate Office: 1st Floor, Kohinoor City Mall, Gate No. 1, Opp. Don Bosco School, Premier Road, Kirol Road, Kurla (West), Mumbai - 400 070.

Toll Free: 1800 1235 835 Website: www.positivebioscience.com Email: info@positivebioscience.com CIN: U93000TN1995PLC030290